OpenAlex Citation Counts

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Executive Function Outcome of Treatment with Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Post-Hoc Analysis of Four Randomized Clinical Trials
Stephen V. Faraone, Roberto Goméni, Joseph T. Hull, et al.
Pediatric Drugs (2021) Vol. 23, Iss. 6, pp. 583-589
Open Access | Times Cited: 13

Showing 13 citing articles:

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder
Azmi Nasser, Joseph T. Hull, Soumya A. Chaturvedi, et al.
CNS Drugs (2022) Vol. 36, Iss. 8, pp. 897-915
Open Access | Times Cited: 40

A Review and an Update on Pharmacological Treatment of Children With Attention-Deficit/Hyperactivity Disorder
Taeyeop Lee, Hyo‐Won Kim
Journal of korean Academy of Child and Adolescent Psychiatry (2025) Vol. 36, Iss. 1, pp. 11-17
Open Access | Times Cited: 1

Synthetic Approaches to the New Drugs Approved During 2021
Emma L. McInturff, Scott P. France, Carolyn A. Leverett, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 15, pp. 10150-10201
Closed Access | Times Cited: 15

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021
Gizem Kaykı-Mutlu, Zinnet Şevval Aksoyalp, Leszek Wojnowski, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2022) Vol. 395, Iss. 8, pp. 867-885
Open Access | Times Cited: 17

Pediatric attention deficit hyperactivity disorder (ADHD): 2022 updates on pharmacological management
Lisa O’Connor, Stephanie Carbone, Anthony Gobbo, et al.
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 9, pp. 799-812
Closed Access | Times Cited: 9

Nonstimulant Treatments for ADHD
Jeffrey H. Newcorn, Beth Krone, Regina Dittmann
Child and Adolescent Psychiatric Clinics of North America (2022) Vol. 31, Iss. 3, pp. 417-435
Open Access | Times Cited: 16

Viloxazine extended-release capsules as an emerging treatment for attention-deficit/hyperactivity disorder in children and adolescents
Vladimir Maletic, Gregory W. Mattingly, Jami Earnest
Expert Review of Neurotherapeutics (2024) Vol. 24, Iss. 5, pp. 443-455
Open Access | Times Cited: 1

Systematic Review of Executive Function Stimulation Methods in the ADHD Population
Carlos Ramos-Galarza, Deyaneira Brito, Brayan Rodríguez, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 14, pp. 4208-4208
Open Access | Times Cited: 1

A post hoc analysis of the effect of viloxazine extended-release capsules on learning and school problems in children and adolescents with attention-deficit/hyperactivity disorder
Stephen V. Faraone, Roberto Goméni, Joseph T. Hull, et al.
European Child & Adolescent Psychiatry (2021) Vol. 32, Iss. 3, pp. 491-499
Open Access | Times Cited: 8

Central Nervous System Disorders and Food and Drug Administration–Approved Drugs
Estella Odoh, Chukwuebuka Egbuna, Chukwuma Micheal Onyegbulam, et al.
(2023), pp. 1-16
Closed Access | Times Cited: 2

Viloxazine: A New Non-Stimulant Treatment for Attention-Deficit/Hyperactivity Disorder (ADHD)
Wiktoria Wilanowska, Anna Gregułą, Karol Stachyrak, et al.
Journal of Education Health and Sport (2024) Vol. 58, pp. 71-85
Open Access

Structural Modeling of Risk-Taking Behaviors Based on Attention Systems with the Mediating Role of Emotion Regulation in Substance Users
Vahid Rezaei Kachi, Elham Foroozandeh, Fatemeh Sadat Tabatabaei Nejad, et al.
journal of Adolescent and Youth Psychological Studies (2024) Vol. 5, Iss. 4, pp. 29-35
Open Access

Viloxazine, a Non-stimulant Norepinephrine Reuptake Inhibitor, for the Treatment of Attention Deficit Hyperactivity Disorder: A 3 Year Update
Hannah W. Haddad, Paul Bryan Hankey, Jimin Ko, et al.
Health psychology research (2022) Vol. 10, Iss. 2
Open Access | Times Cited: 2

Page 1

Cookie	Duration	Description
cookielawinfo-checkbox-advertisement	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Analytics" category .
cookielawinfo-checkbox-functional	1 year	The cookie is set by the GDPR Cookie Consent plugin to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Necessary" category .
cookielawinfo-checkbox-others	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to store the user consent for cookies in the category "Others".
cookielawinfo-checkbox-performance	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to store the user consent for cookies in the category "Performance".
CookieLawInfoConsent	1 year	Records the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSID	session	This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.

Requested Article:

Showing 13 citing articles:

Your Privacy